G. Villafane

Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease

Philippe Hantraye, Aurélie Kas, Maria-Joao Ribeiro, 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.

Y. Samson, P. Remy, M. Peschanski, 1996, Brain : a journal of neurology.

High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

P. Remy, G. Fénelon, E. Audureau, 2018, European journal of neurology.

Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study

L. Itti, P. Brugières, M. Meignan, 2009, Nuclear medicine communications.

Chronic high dose transdermal nicotine in Parkinson's disease: an open trial

I. Macquin-Mavier, P. Maison, P. Césaro, 2007, European journal of neurology.

Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes

J. Gracies, J. David, E. Itti, 2020, Medicine.

Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue

Y. Samson, P. Remy, M. Peschanski, 2003, Movement disorders : official journal of the Movement Disorder Society.

Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study

Y. Agid, A. Bonnet, O. Blin, 2010, Movement disorders : official journal of the Movement Disorder Society.

Can nicotine be used medicinally in Parkinson’s disease?

P. Remy, G. Fénelon, P. Césaro, 2011, Expert review of clinical pharmacology.

Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study

Y. Agid, A. Bonnet, O. Blin, 2010, Movement disorders : official journal of the Movement Disorder Society.